New hope for Hard-to-Treat GI cancers? phase II trial launches

NCT ID NCT06008054

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II study is testing whether a new drug called SI-B003, alone or combined with BL-B01D1 or a PD-1 antibody, can shrink tumors in people with advanced esophageal, gastric, or colorectal cancer. About 376 participants will receive the treatments intravenously every three weeks. The goal is to see how well the drugs work and if they are safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SI-B003 (a drug), BL-B01D1 (also called iza-bren or izalontamab brengitecan), and a PD-1 monoclonal antibody
What this could lead to: If successful, this could point toward new treatment options for people with advanced gastrointestinal cancers that are hard to treat.
What could go wrong: This is an early-phase trial with no guarantee of success. The treatments may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm digestive system neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.